Saniona makes correction in Interim Report
Saniona makes a correction to the interim report for January to June 2015 due to typing errors in the financial highlight section.
Reported EBIT for the first 6 months was KSEK -11,891 (306) and not KSEK -21,738 (-12,445) as stated in the financial highlight section on page 1. The presented numbers referred to total operating expenses for the period and not earnings before interest and tax. It is also to be noted that the Swedish version referred to Profit/Loss after financial items and not earnings before interest and tax as stated in the English version.
There are no other changes to the interim report and it will now be published on Saniona’s homepage.
For more information please contact
Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: firstname.lastname@example.org
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with major pharmaceutical companies including Pfizer Inc., as well as Saniona’s Boston based spinout Ataxion Inc., which is financed by Atlas Venture Inc. and Biogen Idec Inc. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard and 18 employees. Saniona is listed at AktieTorget since April 2014 and has about 2,000 shareholders. The company’s share is traded under the ticker SANION. Read more at www.saniona.com.